NZ529526A - Method and compositions for treating mammalian nerve tissue injuries - Google Patents
Method and compositions for treating mammalian nerve tissue injuriesInfo
- Publication number
- NZ529526A NZ529526A NZ529526A NZ52952602A NZ529526A NZ 529526 A NZ529526 A NZ 529526A NZ 529526 A NZ529526 A NZ 529526A NZ 52952602 A NZ52952602 A NZ 52952602A NZ 529526 A NZ529526 A NZ 529526A
- Authority
- NZ
- New Zealand
- Prior art keywords
- injury
- glycol
- peg
- spinal cord
- nerve
- Prior art date
Links
- 210000000944 nerve tissue Anatomy 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 93
- 239000000203 mixture Substances 0.000 title description 34
- 208000037816 tissue injury Diseases 0.000 title description 6
- 208000014674 injury Diseases 0.000 claims abstract description 140
- 230000006378 damage Effects 0.000 claims abstract description 135
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 128
- 230000004927 fusion Effects 0.000 claims abstract description 106
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 215
- 239000002202 Polyethylene glycol Substances 0.000 claims description 205
- 210000000278 spinal cord Anatomy 0.000 claims description 145
- 239000003795 chemical substances by application Substances 0.000 claims description 118
- 210000005036 nerve Anatomy 0.000 claims description 62
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 60
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 34
- -1 polybutylene Polymers 0.000 claims description 31
- 229920000642 polymer Polymers 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 229920001451 polypropylene glycol Polymers 0.000 claims description 15
- 239000007929 subcutaneous injection Substances 0.000 claims description 13
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 239000007928 intraperitoneal injection Substances 0.000 claims description 6
- 208000037906 ischaemic injury Diseases 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 210000000578 peripheral nerve Anatomy 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 229920006324 polyoxymethylene Polymers 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 229920001748 polybutylene Polymers 0.000 claims description 3
- 238000011084 recovery Methods 0.000 description 93
- 241001465754 Metazoa Species 0.000 description 82
- 241000282472 Canis lupus familiaris Species 0.000 description 80
- 239000012528 membrane Substances 0.000 description 61
- 210000003050 axon Anatomy 0.000 description 48
- 208000020431 spinal cord injury Diseases 0.000 description 45
- 230000003902 lesion Effects 0.000 description 40
- 238000012360 testing method Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 33
- 230000000638 stimulation Effects 0.000 description 32
- 230000003542 behavioural effect Effects 0.000 description 29
- 230000008439 repair process Effects 0.000 description 29
- 206010033892 Paraplegia Diseases 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 230000004044 response Effects 0.000 description 26
- 230000006870 function Effects 0.000 description 25
- 239000003450 potassium channel blocker Substances 0.000 description 24
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 23
- 241000700199 Cavia porcellus Species 0.000 description 22
- 210000004885 white matter Anatomy 0.000 description 22
- 229920001983 poloxamer Polymers 0.000 description 21
- 229960004979 fampridine Drugs 0.000 description 20
- 230000006835 compression Effects 0.000 description 19
- 238000007906 compression Methods 0.000 description 19
- 230000000763 evoking effect Effects 0.000 description 19
- 210000003141 lower extremity Anatomy 0.000 description 19
- 210000004126 nerve fiber Anatomy 0.000 description 19
- 229940125422 potassium channel blocker Drugs 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 18
- 230000000926 neurological effect Effects 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 241000700198 Cavia Species 0.000 description 17
- 108091006146 Channels Proteins 0.000 description 17
- 230000011514 reflex Effects 0.000 description 17
- 238000007789 sealing Methods 0.000 description 17
- 230000003376 axonal effect Effects 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000033001 locomotion Effects 0.000 description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 13
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 229960000502 poloxamer Drugs 0.000 description 13
- 230000006399 behavior Effects 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- 208000020339 Spinal injury Diseases 0.000 description 10
- 230000036982 action potential Effects 0.000 description 10
- 229920001400 block copolymer Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000000653 nervous system Anatomy 0.000 description 10
- 230000000750 progressive effect Effects 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 230000008733 trauma Effects 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 230000002747 voluntary effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 9
- 230000001174 ascending effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 210000001617 median nerve Anatomy 0.000 description 9
- 229920001987 poloxamine Polymers 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000036770 blood supply Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000006735 deficit Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 210000002972 tibial nerve Anatomy 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 206010003084 Areflexia Diseases 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000005684 electric field Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 208000025962 Crush injury Diseases 0.000 description 6
- 102000004257 Potassium Channel Human genes 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 150000002632 lipids Chemical group 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- 108020001213 potassium channel Proteins 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 150000003222 pyridines Chemical class 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 5
- 230000001010 compromised effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 230000036403 neuro physiology Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000034656 Contusions Diseases 0.000 description 4
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000009519 contusion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000003238 somatosensory effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 238000001521 two-tailed test Methods 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 241001269524 Dura Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000015981 conscious proprioception Diseases 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000000991 decompressive effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 230000030214 innervation Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 230000007383 nerve stimulation Effects 0.000 description 3
- 210000005044 neurofilament Anatomy 0.000 description 3
- 238000010984 neurological examination Methods 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000000272 proprioceptive effect Effects 0.000 description 3
- 230000009023 proprioceptive sensation Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000235789 Hyperoartia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010073696 Wallerian degeneration Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229940014425 exodus Drugs 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000037907 haemorrhagic injury Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 238000009608 myelography Methods 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000008734 wallerian degeneration Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical group CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- VJDVWBDSMDTODO-UHFFFAOYSA-N 2-methoxyethyl 4-amino-4-oxobutanoate Chemical compound COCCOC(=O)CCC(N)=O VJDVWBDSMDTODO-UHFFFAOYSA-N 0.000 description 1
- DMKKMGYBLFUGTO-UHFFFAOYSA-N 2-methyloxirane;oxirane Chemical compound C1CO1.C1CO1.CC1CO1 DMKKMGYBLFUGTO-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010067441 Myelomalacia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920011250 Polypropylene Block Copolymer Polymers 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004012 amifampridine Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 108010051874 catalase-polyethylene glycol Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- DPYLONVAWUSRCJ-UHFFFAOYSA-N ethene;2-methyloxirane;oxirane Chemical group C=C.C1CO1.CC1CO1 DPYLONVAWUSRCJ-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000012735 histological processing Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 108010012938 polyethylene glycol-superoxide dismutase Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ543953A NZ543953A (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28620001P | 2001-04-24 | 2001-04-24 | |
| PCT/US2002/013375 WO2002092107A1 (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ529526A true NZ529526A (en) | 2006-06-30 |
Family
ID=23097525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ543953A NZ543953A (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
| NZ529526A NZ529526A (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ543953A NZ543953A (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7837987B2 (enExample) |
| EP (1) | EP1389121B1 (enExample) |
| JP (2) | JP2004527573A (enExample) |
| AT (1) | ATE546146T1 (enExample) |
| AU (2) | AU2002314758B2 (enExample) |
| CA (2) | CA2740056A1 (enExample) |
| ES (1) | ES2382899T3 (enExample) |
| NZ (2) | NZ543953A (enExample) |
| WO (1) | WO2002092107A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582680B1 (en) | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| NZ543953A (en) * | 2001-04-24 | 2007-04-27 | Univ Chicago | Method and compositions for treating mammalian nerve tissue injuries |
| US7147647B2 (en) | 2002-04-26 | 2006-12-12 | Medtronic, Inc. | Sintered titanium tube for the management of spinal cord injury |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| NZ543365A (en) | 2003-04-18 | 2009-02-28 | Biogen Idec Inc | Polymer-conjugated glycosylated neublastin |
| EP1786454B1 (en) * | 2004-08-19 | 2010-07-21 | Biogen Idec MA Inc. | Neublastin variants |
| DE602005022082D1 (de) * | 2004-08-19 | 2010-08-12 | Biogen Idec Inc | Rückfaltung von proteinen der transforming-growth-factor-beta-familie |
| US20060121016A1 (en) * | 2004-10-18 | 2006-06-08 | Lee Raphael C | Methods and compositions for treatment of free radical injury |
| CN101084272B (zh) * | 2004-12-21 | 2011-07-13 | 路博润有限公司 | 组合物 |
| US20070048731A1 (en) * | 2005-05-20 | 2007-03-01 | Neurosilicon | High throughput use-dependent assay based on stimulation of cells on a silicon surface |
| WO2006130599A2 (en) * | 2005-05-31 | 2006-12-07 | Warsaw Orthopedic, Inc. | Compositions and methods for treating a damaged cardiovascular element |
| US20070017530A1 (en) * | 2005-06-10 | 2007-01-25 | Syed Naweed I | Detecting electrical activity and assessing agents for the ability to influence electrical activity |
| US20060287660A1 (en) * | 2005-06-15 | 2006-12-21 | Syed Naweed I | Electrically Stimulating Nerve Regeneration |
| US20060292549A1 (en) * | 2005-06-15 | 2006-12-28 | Neurosilicon | Psychotropic drug screening device based on long-term photoconductive stimulation of neurons |
| JP4907908B2 (ja) * | 2005-06-29 | 2012-04-04 | ルネサスエレクトロニクス株式会社 | 駆動回路及び表示装置 |
| US20070092958A1 (en) * | 2005-07-15 | 2007-04-26 | Syed Naweed I | Method and apparatus for guiding growth of neurons |
| US20070213718A1 (en) * | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
| US7520888B2 (en) * | 2006-02-14 | 2009-04-21 | Warsaw Orthopedic, Inc. | Treatment of the vertebral column |
| US20070213717A1 (en) * | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Biological fusion in the vertebral column |
| US20070227547A1 (en) * | 2006-02-14 | 2007-10-04 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
| TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| ES2450065T3 (es) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF |
| US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
| US8840933B2 (en) | 2006-05-03 | 2014-09-23 | Warsaw Orthopedic, Inc. | Method of treating neuronal injury by administering magnesium chloride and PEG |
| US9675696B2 (en) | 2006-11-14 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
| US8329655B2 (en) | 2007-05-01 | 2012-12-11 | Biogen Idec Ma Inc. | Methods for increasing vascularization |
| US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
| CA2744100C (en) * | 2008-10-21 | 2020-06-30 | The General Hospital Corporation | Cell transplantation |
| US9244060B2 (en) * | 2009-03-26 | 2016-01-26 | Warsaw Orthopedic, Inc. | Site localization and methods for monitoring treatment of disturbed blood vessels |
| US8858924B2 (en) * | 2009-03-26 | 2014-10-14 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
| US9078808B2 (en) * | 2009-03-26 | 2015-07-14 | Warsaw Orthopedic, Inc. | Device to deliver magnesium in PEG formulation |
| US8852566B2 (en) | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
| WO2010111212A1 (en) | 2009-03-26 | 2010-09-30 | Warsaw Orthopedic, Inc. | Methods of identifying potential components for targeted drug delivery compositions |
| CA2758118C (en) | 2009-04-07 | 2019-05-21 | Catholic Healthcare West | Uterine electrical stimulation system and method |
| US20110230785A1 (en) * | 2010-03-16 | 2011-09-22 | ProNerve, LLC | Somatosensory Evoked Potential (SSEP) Automated Alert System |
| BR112013002859B1 (pt) | 2010-08-06 | 2020-10-06 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Método e aparelho para tratamento de células |
| CA3063888C (en) | 2010-10-27 | 2020-12-22 | Dignity Health | Uterine electrical stimulation system and method |
| WO2013173833A1 (en) * | 2012-05-18 | 2013-11-21 | Dignity Health | Electrical stimulation of the cervix |
| US9872983B2 (en) | 2010-10-27 | 2018-01-23 | Dignity Health | Uterine electrical stimulation system and method |
| WO2012161823A1 (en) * | 2011-02-25 | 2012-11-29 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Nerve coaptation apparatus |
| EP2953640B1 (en) * | 2013-02-07 | 2020-04-08 | The Cleveland Clinic Foundation | Nanoencapsulated superoxide dismutase and catalase for treating spinal cord injury |
| PL3138031T3 (pl) | 2014-04-28 | 2023-04-11 | Yeda Research And Development Co., Ltd. | Sposób i urządzenie do przewidywania odpowiedzi na pokarm |
| GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
| EP3658072B1 (en) | 2017-07-26 | 2024-03-13 | Neuraptive Therapeutics, Inc. | Device for administering therapeutics to a nerve |
| US12458411B2 (en) | 2017-12-07 | 2025-11-04 | Augmedics Ltd. | Spinous process clamp |
| EP3787543A4 (en) | 2018-05-02 | 2022-01-19 | Augmedics Ltd. | REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM |
| US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
| US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
| US12178666B2 (en) | 2019-07-29 | 2024-12-31 | Augmedics Ltd. | Fiducial marker |
| JP7653164B2 (ja) * | 2019-09-27 | 2025-03-28 | バージニア コモンウェルス ユニバーシティー | 組織を修復または増加させるための組成物および方法 |
| US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
| WO2021150773A1 (en) * | 2020-01-21 | 2021-07-29 | The Penn State Research Foundation | Methods and materials for treating nerve injury and/or promoting wound healing |
| US11389252B2 (en) | 2020-06-15 | 2022-07-19 | Augmedics Ltd. | Rotating marker for image guided surgery |
| US20230190676A1 (en) * | 2020-07-09 | 2023-06-22 | Musc Foundation For Research Development | Methods of protecting cells from insults |
| US12239385B2 (en) | 2020-09-09 | 2025-03-04 | Augmedics Ltd. | Universal tool adapter |
| US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
| US12150821B2 (en) | 2021-07-29 | 2024-11-26 | Augmedics Ltd. | Rotating marker and adapter for image-guided surgery |
| EP4387552A4 (en) | 2021-08-18 | 2025-04-30 | Augmedics Ltd. | AUGMENTED REALITY SURGICAL SYSTEM USING DEPTH SENSING |
| WO2023203521A1 (en) | 2022-04-21 | 2023-10-26 | Augmedics Ltd. | Systems and methods for medical image visualization |
| US12268677B2 (en) | 2022-04-27 | 2025-04-08 | The Penn State Research Foundation | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) |
| IL319523A (en) | 2022-09-13 | 2025-05-01 | Augmedics Ltd | Augmented reality glasses for image-guided medical intervention |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369769A (en) | 1980-06-13 | 1983-01-25 | Edwards Charles C | Spinal fixation device and method |
| US4599354A (en) | 1985-03-11 | 1986-07-08 | Morton Shulman | Composition and method for producing prolonged pain relief |
| US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US4919140A (en) | 1988-10-14 | 1990-04-24 | Purdue Research Foundation | Method and apparatus for regenerating nerves |
| IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| NL9000634A (nl) | 1990-03-20 | 1991-10-16 | Catharina Ziekenhuis Stichting | Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding. |
| CA2075928A1 (en) * | 1991-01-11 | 1992-07-12 | Roger W. Hackett | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material |
| CN1069741A (zh) | 1991-03-19 | 1993-03-10 | 西特克斯公司 | 具有改进的生物活性的聚氧丙烯/聚氧乙烯共聚物 |
| US5470568A (en) | 1992-02-13 | 1995-11-28 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for cell repair |
| US5324322A (en) * | 1992-04-20 | 1994-06-28 | Case Western Reserve University | Thin film implantable electrode and method of manufacture |
| US5605687A (en) * | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| DE69322707T2 (de) | 1992-07-31 | 1999-08-19 | Bristol-Myers Squibb Company | Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins |
| CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
| CN1103698C (zh) * | 1995-02-14 | 2003-03-26 | 东丽株式会社 | 平版印刷版及平板印刷版原版 |
| JPH09315972A (ja) | 1996-03-22 | 1997-12-09 | Chugai Pharmaceut Co Ltd | 脊髄損傷治療剤 |
| US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| EP1024812B1 (en) | 1997-03-19 | 2007-01-24 | Sky High, LLC | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| US7582680B1 (en) * | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| AU4363600A (en) * | 1999-04-22 | 2000-11-10 | Department Of The Army, U.S. Government | Treatment of and/or prophylaxis against brain and spinal cord injury |
| NZ543953A (en) | 2001-04-24 | 2007-04-27 | Univ Chicago | Method and compositions for treating mammalian nerve tissue injuries |
| US7199110B2 (en) | 2002-12-30 | 2007-04-03 | Purdue Research Foundation | Method of treatment for spinal cord injury |
-
2002
- 2002-04-24 NZ NZ543953A patent/NZ543953A/en not_active IP Right Cessation
- 2002-04-24 JP JP2002589024A patent/JP2004527573A/ja active Pending
- 2002-04-24 WO PCT/US2002/013375 patent/WO2002092107A1/en not_active Ceased
- 2002-04-24 ES ES02741682T patent/ES2382899T3/es not_active Expired - Lifetime
- 2002-04-24 NZ NZ529526A patent/NZ529526A/en not_active IP Right Cessation
- 2002-04-24 US US10/132,542 patent/US7837987B2/en not_active Expired - Fee Related
- 2002-04-24 AT AT02741682T patent/ATE546146T1/de active
- 2002-04-24 EP EP02741682A patent/EP1389121B1/en not_active Expired - Lifetime
- 2002-04-24 AU AU2002314758A patent/AU2002314758B2/en not_active Ceased
- 2002-04-24 CA CA2740056A patent/CA2740056A1/en not_active Abandoned
- 2002-04-24 CA CA2445612A patent/CA2445612C/en not_active Expired - Fee Related
-
2004
- 2004-07-28 US US10/901,481 patent/US9687502B2/en not_active Expired - Fee Related
-
2006
- 2006-03-01 AU AU2006200866A patent/AU2006200866B2/en not_active Ceased
-
2009
- 2009-02-23 JP JP2009039488A patent/JP2009112835A/ja active Pending
- 2009-07-23 US US12/508,184 patent/US8460646B2/en not_active Expired - Fee Related
-
2013
- 2013-06-07 US US13/912,499 patent/US9101655B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1389121A4 (en) | 2006-11-02 |
| US9687502B2 (en) | 2017-06-27 |
| CA2445612C (en) | 2011-10-25 |
| AU2006200866B2 (en) | 2007-11-08 |
| AU2006200866A1 (en) | 2006-03-23 |
| ATE546146T1 (de) | 2012-03-15 |
| EP1389121A1 (en) | 2004-02-18 |
| US20100016444A1 (en) | 2010-01-21 |
| ES2382899T3 (es) | 2012-06-14 |
| WO2002092107A1 (en) | 2002-11-21 |
| US20030118545A1 (en) | 2003-06-26 |
| CA2445612A1 (en) | 2002-11-21 |
| US8460646B2 (en) | 2013-06-11 |
| US9101655B2 (en) | 2015-08-11 |
| EP1389121B1 (en) | 2012-02-22 |
| JP2009112835A (ja) | 2009-05-28 |
| US20140100289A1 (en) | 2014-04-10 |
| AU2002314758B2 (en) | 2006-06-01 |
| US20050069520A1 (en) | 2005-03-31 |
| CA2740056A1 (en) | 2002-11-21 |
| US7837987B2 (en) | 2010-11-23 |
| NZ543953A (en) | 2007-04-27 |
| JP2004527573A (ja) | 2004-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2445612C (en) | Methods and compositions for treating mammalian nerve tissue injuries | |
| AU2002314758A1 (en) | Method and composition for treating mammalian nerve tissue injuries | |
| BLIGHT et al. | The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial | |
| Awadzi et al. | The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis | |
| Laverty et al. | A preliminary study of intravenous surfactants in paraplegic dogs: polymer therapy in canine clinical SCI | |
| Somjen | Mechanisms of spreading depression and hypoxic spreading depression-like depolarization | |
| Shi et al. | Functional reconnection of severed mammalian spinal cord axons with polyethylene glycol | |
| Gomez-Amaya et al. | Neural reconstruction methods of restoring bladder function | |
| Borgens | Cellular engineering: molecular repair of membranes to rescue cells of the damaged nervous system | |
| EP0626848B1 (en) | The use of 4-aminopyridine in the treatment of pain and spasticity resulting from spinal cord injury | |
| Park et al. | TissueGene-C induces long-term analgesic effects through regulation of pain mediators and neuronal sensitization in a rat monoiodoacetate-induced model of osteoarthritis pain | |
| US7582680B1 (en) | Methods and compositions for treating mammalian spinal cord injuries | |
| Rotterman et al. | Structural preservation does not ensure function at sensory Ia–motoneuron synapses following peripheral nerve injury and repair | |
| Miao et al. | Mechanosensitive duodenal afferents contribute to vagal modulation of inflammation in the rat | |
| Bitar Alatorre et al. | Critical ischemia time in a model of spinal cord section. A study performed on dogs | |
| Seitz et al. | Toxic effects of triethyldodecylammoniumbromide (TEA-C12) on myelinated nerve fibers and blood-nerve barrier in the mouse | |
| Añor | Monoparesis | |
| Weiss et al. | Stem Cell Ophthalmology Treatment Study (SCOTS): Autologous bone-marrow derived stem cells in the treatment of hereditary macular degeneration | |
| Francis et al. | Benzalkonium Chloride–Induced Denervation of Orbicularis Oculi Muscle in Rabbits | |
| KR20200105814A (ko) | 보툴리눔 요법의 부작용 치료 | |
| Fox et al. | The effect of angiography on the electrophysiological state of the spinal cord: a study in control and traumatized cats | |
| Borgens | Recovery of Behavioral and Physiological Function In Vivo | |
| Soto | Critical ischemia time in a model of spinal cord section. A study performed on dogs | |
| WO2020023755A1 (en) | Treatment for ischemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| ASS | Change of ownership |
Owner name: PURDUE RESEARCH FOUNDATION, US Free format text: OLD OWNER(S): THE UNIVERSITY OF CHICAGO; PURDUE RESEARCH FOUNDATION |
|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 APR 2016 BY COMPUTER PACKAGES INC Effective date: 20150331 |
|
| LAPS | Patent lapsed |